Kenvue (KVUE) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
21 May, 2026Opening remarks and agenda
Meeting called to order at 9:00 A.M. Eastern Time, with introductions of the Board and management team.
Rules of conduct and meeting procedures were reviewed to ensure orderly proceedings.
Board and executive committee updates
All 12 director nominees, including experienced leaders from various industries, were introduced and recommended for election.
Committee chairs and key management, including the General Counsel and Corporate Secretary, were present.
Shareholder proposals
Three proposals were presented: election of directors, advisory vote on executive compensation, and ratification of the independent auditor.
The board recommended approval of all proposals.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Kenvue
- Third consecutive quarter of sales growth, margin pressure, and Kimberly-Clark merger progress.KVUE
Q2 2026 - Net income jumped 47% on higher sales and margins, with restructuring and a major merger pending.KVUE
Q1 2026 - Shareholders will vote on a merger, director elections, executive pay, and auditor ratification.KVUE
Proxy filing - Proxy statement solicits shareholder votes for annual meeting with no filing fee required.KVUE
Proxy filing - Q4 sales and margins improved, but full year sales declined; Kimberly-Clark deal pending.KVUE
Q4 2025 - Merger and compensation proposals were approved by stockholders, with final results pending SEC filing.KVUE
AGM 2026 - A $48.7B merger forms a global health leader, targeting $2.1B in synergies by 2026.KVUE
M&A Announcement - Q2 saw 1.5% organic growth, margin expansion, and a $488M impairment hit net income.KVUE
Q2 2024 - Q1 2025 net sales fell 3.9% and adjusted EPS was flat, pressured by tariffs and FX.KVUE
Q1 2025